Division of Teva Pharmaceutical Industries Ltd.
Latest From Salmedix Inc.
The Massachusetts biotech has remained well-funded despite shying away from venture capital investors and seeking funds from private investors.
Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- North America
- Parent & Subsidiaries
- Teva Pharmaceutical Industries Ltd.
- Senior Management
David S Kabakoff, Chmn. & CEO
Anita Busquets, CFO
Alan S Rosenthal, MD, Pres. & CSO
Patrick Multani, VP, Clinical Dev.
- Contact Info
Phone: (858) 622-5050
9380 Judicial Dr.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.